Price
No data yet.
Social Signal Score
Analyst Ratings
30 analystsRevenue
$113.04M+71.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas A. McCourt
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 100
- Beta
- 0.22
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- -2.06
Financials
Revenue
$113.04M+71.0%Net Income
$51.29MEBITDA
$81.39MFree Cash Flow
$58.28MEPS (diluted)
$0.31Shares Outstanding (diluted)
165.45M+14.6%Operating Expenses
$33.73MCash & Debt
$79.13MReturn of Capital
$0.00Revenue by Segment (annual)
$298.22MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $296.15M | $24.02M | $0.15 |
| 2024 | $351.41M | $880.0K | $0.01 |
| 2023 | $442.74M | $-1.00B | $-6.45 |
| 2022 | $410.60M | $175.06M | $1.13 |
| 2021 | $413.75M | $528.45M | $3.26 |
| 2020 | $389.52M | $106.18M | $0.67 |
| 2019 | $428.41M | $21.50M | $0.38 |
| 2018 | $346.64M | $-282.37M | $-1.85 |
| 2017 | $298.28M | $-116.94M | $-0.79 |
| 2016 | $273.96M | $-81.71M | $-0.56 |
| 2015 | $149.56M | $-142.67M | $-1.00 |
| 2014 | $76.44M | $-189.62M | $-1.39 |
| 2013 | $22.88M | $-272.81M | $-2.35 |
| 2012 | $150.25M | $-72.62M | $-0.68 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.22
- Implied price
- $4.79
- Return from $3.82
- 4.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.38 — -37.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -2.0% | -10.9% | -7.8% | -5.1% | -2.6% | -0.4% |
| 3.0% | -6.4% | -3.1% | -0.2% | 2.4% | 4.7% |
| 8.0% | -1.8% | 1.6% | 4.6% | 7.3% | 9.8% |
| 13.0% | 2.7% | 6.3% | 9.5% | 12.3% | 14.9% |
| 18.0% | 7.2% | 11.0% | 14.3% | 17.3% | 19.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
170+142.86%Social Signal Score
Mentions (4)
- Newszacks.com·3d ago·Positive
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
View source ↗ - Newsseekingalpha.com·3d ago·Positive
Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide, not Linzess, due to looming generic competition. IRWD's Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029 and Medicare price cuts impacting margins. Apraglutide's value depends on successful STARS-2 trial results and timely approval, with peak sales modeled conservatively at $456 million.
View source ↗ - Newszacks.com·19d ago·Positive
Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Ironwood Pharmaceuticals: High Dependence On Its Next Trial Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029–2030. IRWD raised LINZESS full-year U.S. net sales guidance to $1.15–$1.2 billion and its own revenue forecast to $460–$485 million. Apraglutide, IRWD's pipeline asset for SBS-IF, showed statistically significant Phase 3 results and is key to future value.
View source ↗
Earnings
Mon, Nov 9(in 4 weeks)
Consensus estimate $0.32 per share
Typical surprise -3.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.31 vs $0.32miss
- Thu, May 7$0.24 vs $0.07beat
- Wed, Feb 25$-0.01 vs $0.02miss
- Mon, Nov 10$0.24 vs $0.09beat
- Thu, Aug 7$0.14 vs $-0.02beat
- Wed, May 7$-0.23 vs $-0.05miss
Estimates and results for IRWD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IRWD officers and directors.
- Bought
- —
- Sold
- $24.7m
0 trades
40 trades
- Silver Ronaldsold
- Mchugh Juliesold
- Denner Alexander Jsold
- Denner Alexander Jsold
- John Minardosold
- Shetzline Michaelsold
- Gaskins Tammi Lsold
- Mccourt Thomas Asold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IRWD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.